The results are in from drug giant Merck's most recent trial of a vaccine for Ebola — and they look pretty good:
The vaccine was 100 percent effective when it was tested on more than 4,000 people who were in close contact with Ebola patients in the African nation of Guinea, the World Health Organization said, citing a study published today in the Lancet medical journal. The trial of the vaccine, called Ebola ca suffit — "Ebola, that's enough" in French — began on March 23. [Bloomberg]
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
-
Bird flu one mutuation from human threat, study findsSpeed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
-
Dark chocolate tied to lower diabetes riskSpeed Read The findings were based on the diets of about 192,000 US adults over 34 years
-
ACA opens 2025 enrollment, enters 2024 raceSpeed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
-
McDonald's sued over E. coli linked to burgerSpeed Read The outbreak has sickened at least 49 people in 10 states and left one dead
-
Texas dairy worker gets bird flu from infected cowSpeed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
-
Dengue hits the Americas hard and earlySpeed Read Puerto Rico has declared an epidemic as dengue cases surge
-
US bans final type of asbestosSpeed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
